Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis

IMPORTANCE: Pre-exposure prophylaxis with neutralizing SARS-CoV-2 monoclonal antibodies (mAbs PrEP) prevents infection and reduces hospitalizations and the duration thereof for COVID-19 and death among high-risk individuals. However, reduced effectiveness due to a changing SARS-CoV-2 viral landscape...

Descripción completa

Detalles Bibliográficos
Autores principales: Popping, Stephanie, Nichols, Brooke E., Appelman, Brent, Biemond, Jason J., Vergouwe, Magda, Rosendaal, Frits R., van der Valk, Marc, de Bree, Godelieve J., Wiersinga, W. Joost, Birnie, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326646/
https://www.ncbi.nlm.nih.gov/pubmed/37410460
http://dx.doi.org/10.1001/jamanetworkopen.2023.21985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326646/
https://www.ncbi.nlm.nih.gov/pubmed/37410460
http://dx.doi.org/10.1001/jamanetworkopen.2023.21985

Ejemplares similares